Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Swedish Orphan Biovitrum Logo
Swedish Orphan Biovitrum Growth Score
73
CB Rank
24436
Heat Score
75
Swedish Orphan Biovitrum is a global biopharma company that manufactures and supplies rare disease medicines.
Founded
obfuscation
PublicPost-IPO Debt Solna, Stockholms Lan, Sweden1001-5000 www.sobi.com/en
Biotechnology
Genetics
Health Care
Medical
Pharmaceutical
Overview

Swedish Orphan Biovitrum
Total Funding
obfuscation
Growth Score
73
Heat Score
75

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score73
-12 pts
in past quarter
Heat Score 75
-4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Swedish Orphan Biovitrum

CB Rank
24436
Swedish Orphan Biovitrum is a global biopharma company that manufactures and supplies rare disease medicines.
Founded
obfuscation
PublicPost-IPO Debt Solna, Stockholms Lan, Sweden1001-5000 www.sobi.com/en
Biotechnology
Genetics
Health Care
Medical
Pharmaceutical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

Details

Legal Name Swedish Orphan Biovitrum AB
Also Known As Sobi, Biovitrum
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  STO:SOBI
Company Type For Profit
Founders  Bo Jesper Hansen, Johan Kördel, Rishu Sood
About the Company

Swedish Orphan Biovitrum engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. It offers drugs for the treatment of rare and life-threatening diseases, such as cardiology, diseases affecting immunocompromised patients, genetic disorders, haematology, infectious diseases, metabolic disorders,

oncology, palliative care, poison control, respiratory diseases, and urology.

Phone Number (468)697-2000
Contact Email info@sobi.com
Predictions & Insights

Growth Insight

See this Growth Insight
Swedish Orphan Biovitrum is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Growth Prediction

See this Growth Prediction

Products & Services

Elocta
A treatment for haemophilia A that helps manage bleeding episodes by replacing deficient clotting factor VIII.
Alprolix
A therapy for haemophilia B that replaces deficient clotting factor IX to prevent and control bleeding.

Research & Development

Swedish Orphan Biovitrum is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Swedish Orphan Biovitrum Logo
Post-IPO Debt - Swedish Orphan Biovitrum
—
obfuscation
— Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Alta Partners Logo
Alta Partners
No
Venture Round - Swedish Orphan Biovitrum Logo
Venture Round - Swedish Orphan Biovitrum
—
Alta Partners Logo
Alta Partners
No
Venture Round - Swedish Orphan Biovitrum Logo
Venture Round - Swedish Orphan Biovitrum
—
Alta Partners Logo
Alta Partners
No
Venture Round - Swedish Orphan Biovitrum Logo
Venture Round - Swedish Orphan Biovitrum
—
Alta Partners Logo
Alta Partners
No
Venture Round - Swedish Orphan Biovitrum Logo
Venture Round - Swedish Orphan Biovitrum
—
Alta Partners Logo
Alta Partners
No
Venture Round - Swedish Orphan Biovitrum Logo
Venture Round - Swedish Orphan Biovitrum
—

Investments

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 6
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation

Investment Breakdown

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 6
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
obfuscation
Apellis Pharmaceuticals Logo
Apellis Pharmaceuticals
Yes
Post-IPO Debt - Apellis Pharmaceuticals Logo
Post-IPO Debt - Apellis Pharmaceuticals
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 1001-5000 Employee Profiles 8 Board Members and Advisors 6 Contacts 929

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

37,573
1.89%
 in past month

IT Spend

$68.3MThis year, Swedish Orphan Biovitrum is projected to spend $68.3M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Demand-Supply Balancing Logo
Demand-Supply Balancing
100
Remote Surveys Logo
Remote Surveys
99
Mission Assurance Logo
Mission Assurance
98

Actively Used Products

27Swedish Orphan Biovitrum uses 27 technology products and services including HTML5, Bootstrap, and  Google Maps API, according to G2 Stack.

Active Website Tech Count

70Swedish Orphan Biovitrum is actively using 70 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  HSTS.

Total IP

134The intellectual property of Swedish Orphan Biovitrum includes 39 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Swedish Orphan Biovitrum has registered 95 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Swedish Orphan Biovitrum's headquarters? Swedish Orphan Biovitrum is located in Solna, Stockholms Lan, Sweden.Who invested in Swedish Orphan Biovitrum? Swedish Orphan Biovitrum has 2 investors including Alta Partners and  HBM Healthcare Investments.When was the last funding round for Swedish Orphan Biovitrum? Swedish Orphan Biovitrum closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Swedish Orphan Biovitrum's competitors? Alternatives and possible competitors to Swedish Orphan Biovitrum may include Sanofi, Alnylam Pharmaceuticals, and  Galderma.How much funding has Swedish Orphan Biovitrum raised to date? Swedish Orphan Biovitrum has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(0deebd1 1)
|